The CRISPR Medicine Conference

Important Dates for the CRISPR Medicine Conference 2024

Before the Event:

September 1^st, 2023: Registration & abstract submissions open
December 1^st, 2023: Early bird registration deadline
January 5^th, 2024: Abstract submission deadline
February 16^th, 2024: Oral and poster notifications & final programme available
April 21^st, 2024: Registration deadline
April 22^nd, 2024: Abstract publication in the CRISPR Medicine News portal

Event:

April 22^nd, 2024: Virtual event
April 23-25^th, 2024: In-person event in Copenhagen, Denmark

Welcome

The first CRISPR Medicine Conference will take place in Copenhagen, Denmark, on the 23-25^th April 2024 (virtual event 22^nd April). This event will bring European CRISPR research to the forefront, with 6 main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.

This will be a hybrid event with a strong focus on in-person attendance and on-demand virtual content. The conference will include talks by reputable speakers from academia and industry, as well as several workshops focused on developing useful skills for a successful career in gene editing.

You can register to attend the event and submit an abstract directly through this website. Our separate in-person and virtual poster sessions will allow any type of attendee to present and discuss their research with their peers. The top-scoring abstracts will be presented as oral presentations and the authors will be interviewed by CRISPR Medicine News, which boasts an audience of over 20,000 readers per month.

Once you have registered, you will be able to explore the content and see the list of participants.

If you have any questions, please refer to our FAQ section or contact CRISPRMED24 staff at info@crisprmedicineconference.com

**CRISPRMED24 Newsletter - Sign up here**

Confirmed Speakers

Alessia Cavazza

University College London, United Kingdom

Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health.
Google Scholar ORCIID LinkedIn Lab Webpage
André Choulika

Cellectis

CEO at Cellectis.
LinkedIn Company Webpage
André Cohnen

Bayer AG

Head of Genomic Medicine at Bayer.
ORCIID LinkedIn Company Webpage
Anna Cereseto

University of Trento, Italy

Professor. and Vice-Director of Department at University of Trento, and Co-Founder of Alia Therapeutics.
Google Scholar ORCIID LinkedIn Lab Webpage
Avencia Sanchez-Mejias

INTEGRA Therapeutics

CEO and Co-founder at INTEGRA Therapeutics.
Google Scholar ORCIID LinkedIn Company Webpage
Ayal Hendal

Bar-Ilan University, Israel

Principal Investigator and Group leader at Bar-Ilan University, Israel.
Google Scholar ORCIID LinkedIn Lab Webpage
Ben Kleinstiver

Harvard Medical School and Massachusetts General Hospital

Assistant Professor at the Center for Genomic Medicine, Harvard Medical School. MGH Research Scholar at Massachusetts General Hospital.
Google Scholar ORCIID LinkedIn Lab Webpage
Bernhard Schmierer

Karolinska Institutet, Sweden

Head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden.
Google Scholar ORCIID LinkedIn Lab Webpage
Christian Groendahl

SNIPR Biome

CEO and Co-founder at SNIPR Biome.
LinkedIn Company Webpage
Jan Gorodkin

University of Copenhagen, Denmark

Prof. and Group leader at University of Copenhagen, Denmark.
Google Scholar ORCIID LinkedIn Lab Webpage
Karina Thorn

Novo Nordisk

Corporate Vice President, PhD, RNA and Gene Therapies, Global Research Technologies at Novo Nordisk.
LinkedIn Company Website
Kevin Holden

Synthego

Head of Science & Applied Research at Synthego.
ORCIID Linkedin Company Webpage
Manuel Kaulich

Goethe University Frankfurt, Germany

Prof. at Goethe University Frankfurt, Germany and CSO at Vivlion.
Google Scholar ORCIID LinkedIn Lab Webpage Company Webpage
Marcello Maresca

AstraZeneca AB

Senior Director of Genome Engineering Team at AstraZeneca.
ORCIID LinkedIn Company Webpage
Pia Johansson

Lund University, Sweden

Scientific Coordinator of the Cell and Gene Therapy Core at Lund University.
Google Scholar ORCIID LinkedIn Lab Webpage
Rasmus O. Bak

Aarhus University, Denmark

Ass. Prof. at the Department of Biomedicine at Aahrus University and Co-Founder of UNIKUM Therapeutics.
Google Scholar ORCIID LinkedIn Lab Webpage
Sekar Kathiresan

Verve Therapeutics

CEO and Founder at Verve Therapeutics.
LinkedIn Company Webpage
Toni Cathomen

University of Freiburg, Germany

Prof. and Director at the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg.
Google Scholar ORCIID LinkedIn Institute Webpage
Xavier Duportet

Eligo Bioscinece

CEO and Co-founder at Eligo Bioscience.
Google Scholar LinkedIn Company Webpage
Yonglun Luo

Aarhus University, Denmark

Prof. of Gene and Stem Cell Technology at Aarhus University, Denmark and Executive Director at the Lars Bolund Institute of Regenerative Medicine, China.
Google Scholar ORCIID LinkedIn Lab Webpage

Scientific Committee

· Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
· Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
· Alessia Cavazza, Ass. Prof., Group Leader, University College London Greater Ormond Street Institute of Child Health, England
· Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy at University of Trento, Italy
· Karen O´Hanlon Cohrt, Chief Editor CMN

Organising Committee

· Karen O´Hanlon Cohrt, Chief Editor, CRISPR Medicine News
· Gorm Palmgren, Science Writer and Editor, CRISPR Medicine News
· Jens-Ole Bock, Founder, CRISPR Medicine News
· Antonio Carusillo, Science Writer, CRISPR Medicine News
· Manel Lladó, Science Writer, CRISPR Medicine News

· Rebecca Roberts, Science Writer and Editor, CRISPR Medicine News